產前篩檢市場－策略分析與預測（2026-2035）

預計產前篩檢市場規模將從 2026 年的 108 億美元成長到 2035 年的 200 億美元，複合年成長率為 7.1%。

受非侵入性基因組評估模式轉移、孕婦年齡成長以及基於cfDNA的篩檢在臨床上日益普及等因素的驅動，產前篩檢市場正經歷顯著的變革。這一市場演變的特點在於，人們日益認知到，早期識別胎兒染色體異常、遺傳疾病以及某些妊娠相關併發症，能夠實現知情的臨床管理、遺傳諮詢和個性化的孕期規劃，同時避免孕婦承受檢測帶來的風險。次世代定序、微陣列分析和人工智慧的融合，使得產前基因評估更加快速、準確且全面。隨著孕婦年齡的成長，胎兒染色體異常的機率也隨之增加，醫生對早期基因組評估的支持度不斷提高，推動了篩檢在醫療保健系統中的廣泛應用。各國政府、專業協會和監管機構也不斷更新其產前篩檢建議，以反映新的臨床證據，並支持更廣泛地採用檢驗的篩檢技術。隨著基因組檢測、檢查室自動化和數位報告平台的大量投資，產前篩檢正在成為複雜的母胎醫學和人群層面孕產婦保健策略的基礎要素。

市場促進因素

• 非侵入性產前篩檢(NIPS) 的臨床應用日益廣泛，是產前篩檢市場的主要驅動力。 NIPS 因其分析靈敏度高且不會為孕婦帶來相關風險，而被廣泛接受為第一線基因篩檢方法。隨著醫療專業人員對更早、更可靠的胎兒染色體評估的需求不斷成長，臨床實踐正加速轉向基於無細胞 DNA (cfDNA) 的檢測方法。這種轉變減少了對侵入性診斷程序的依賴，同時也提高了患者對產前基因評估的接受度。診斷公司正在擴大檢查室容量和定序基礎設施，以應對日益成長的檢測需求。臨床可靠性的提高以及產前篩檢在常規產科護理中的廣泛應用，對市場產生了積極影響，推動了產前篩檢使用量的持續成長。高齡生產數量的增加進一步加速了市場成長，因為她們對基因篩檢的需求也隨之增加。高齡生產仍然是胎兒染色體異常最顯著的臨床風險因素之一。在許多國家，由於教育程度的提高、勞動參與率的增加以及影響生育決策的社會經濟因素，生育年齡普遍推遲。這種人口結構的變化推動了對全面產前遺傳評估的需求成長，無論妊娠屬於中等風險還是高風險。醫療機構正在懷孕初期採用分子篩檢，以支持知情的臨床管理。次世代定序技術的不斷進步提高了分析準確性和檢查室處理能力。與傳統分子技術相比，NGS 具有更高的擴充性，並透過對胎兒遊離 DNA 的全面評估提高了分析準確性。隨著製造商最佳化工作流程效率和生物資訊整合，定序平台的速度更快、自動化程度更高。這項技術進步降低了營運成本，同時促進了集中式檢查室網路的更廣泛應用。政府和專家對產前遺傳篩檢的支持力道不斷加大，正在加速基於指南的實施。各國醫療機構都認知到產前遺傳篩檢是婦幼保健的重要組成部分，因為早期發現有助於及時進行諮詢和妊娠管理。

市場限制因素

• 在一些發展中醫療體系中，儘管臨床證據不斷增強，但有限的保險覆蓋範圍限制了先進產前基因篩檢的常規應用。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。圍繞產前基因訊息的倫理、法律和社會問題，在一些國家持續影響監管和病人的接受度。產前基因訊息的敏感度也給其應用帶來了挑戰。遺傳諮詢和專業分子診斷檢查室的可近性差異，限制了農村和資源匱乏地區的篩檢。專業諮詢師和檢查室的短缺阻礙了先進篩檢的廣泛應用。複雜且區域差異大的法規，給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對技術和篩檢類型的深入了解

• 技術發展趨勢的特徵是整合基因組平台、自動化和人工智慧驅動的分析日益重要。新一代定序（NGS）已成為領先的技術平台，能夠透過高通量和擴充性的檢測流程對胎兒遊離DNA進行全面分析。隨著定序成本的降低和生物資訊學的進步，營運效率不斷提高，診斷服務提供者也擴大採用先進的定序系統。這種技術變革使得在不顯著增加檢查室複雜性的前提下，能夠提供更廣泛的檢測項目。製造商不斷改進定序化學製程、自動化和軟體整合，以提高高通量檢查室的分析一致性。細分市場分析表明，非侵入性產前檢測（NIPS）是最大的需求來源。這是因為它兼具高分析性能和最大限度降低母嬰臨床風險的特點。隨著臨床證據不斷證明其在常見染色體非整倍體檢測方面優於傳統的血清學檢測，醫療保健提供者也越來越推薦遊離DNA篩檢。染色體數目異常篩檢是臨床應用最廣泛的領域，因為21三體症、18三體症和13三體症仍然是產前基因評估的主要適應症。隨著醫療專業人員優先考慮早期發現需要確診和專業臨床管理的妊娠，臨床需求不斷成長。診斷檢查室是主要的終端用戶，醫院和專科診所也不斷擴展其篩檢能力。人工智慧的整合變得越來越重要，因為它能夠透過改進突變分類、品質評估和提高檢查室工作流程效率來增強基因組數據的解讀。

競爭格局與策略展望

• 競爭格局包括成熟的診斷和定序公司，以及專門提供產前基因組分析、檢查室和檢測服務的供應商。羅氏依然保持著策略優勢，它擁有全球最大的體外診斷產品組合之一，並在分子診斷、PCR技術、定序解決方案和自動化檢測系統方面擁有豐富的專業知識，能夠為臨床檢查室提供貫穿整個產前檢測流程的支援。 Illumina保持著戰略領先地位，其定序平台是全球大部分產前基因組檢測的基礎技術。該公司專注於定序化學、自動化和生物資訊整合的進步，以提高檢查室效率和分析能力。 Natera專注於無細胞DNA檢測和支持生殖健康的專有分子演算法，並透過其Panorama技術的廣泛臨床檢驗贏得了醫生的高度認可。 Revvity透過整合生殖健康診斷、檢查室自動化、生命科學和基因組學技術，確立了其獨特的市場地位。 Quest Diagnostics憑藉其龐大的診斷檢查室網路脫穎而出，該網路是北美最大的診斷實驗室網路之一，為醫生提供廣泛的產前基因檢測服務。 Labcorp持續佔有重要的策略地位，將全國性的診斷檢查室運作與生殖健康領域的專業基因組檢測服務結合。兩家公司都在透過增強基因組檢測組合、檢查室自動化和創新數位報告平台來拓展產品系列。近期的一項重大進展是Myriad Genetics推出了FirstGene，這是一種多參數產前篩檢，可從妊娠8週開始同時篩檢四個產前基因。在2026年國際產前診斷學會（ISPD）年會上，Gene Solutions展示了產前基因組分析和女性健康方面的證據和臨床進展，重點介紹了與無創產前檢測（NIPT）相結合的攜帶者篩檢和人工智慧驅動的妊娠風險評估。 EDAN發布了Nano OB Assist，這是一款由人工智慧驅動的手持式超音波診斷設備，旨在擴大產前篩檢的覆蓋範圍，即使在資源匱乏的環境中也能進行篩檢。地理擴張仍然是一項重要的策略重點，各公司都將目光投向了快速成長的亞太地區和醫療基礎設施正在發展的新興市場。

簡明結論

• 受非侵入性產前檢測（NIPT）普及率提高、人口結構變化和技術創新等因素的推動，產前篩檢市場預計將持續成長。從傳統篩檢轉向全面的非侵入性基因組評估，標誌著母胎醫學領域的根本性變革。儘管保險報銷、倫理考量和醫療資源取得方面的挑戰依然存在，但對技術、夥伴關係和實證醫學的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，產前篩檢正逐步發展成為精準孕產婦保健的基礎要素，在全球醫療體系中支持早期發現、知情決策和改善治療效果。

本報告的主要益處：

• 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
• 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
• 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
• 實用建議：我們支援制定策略決策，以開發新的收入來源。
• 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

• 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
• 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
• 競爭對手定位、策略和市場佔有率分析
• 營收成長率及預測分析：依業務板塊及地區（國家）分類
• 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

• 市場概述
• 主要分析結果
• 分析師意見
• 策略建議

第2章 分析方法

• 分析設計
• 資料收集和分析方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球產前篩檢市場：概況、市場規模與預測

• 市場定義和範圍
• 妊娠和產前篩檢概述
• 產業變化
• 主要市場趨勢
• 實際成果值市場規模分析
• 市場預測
• 疾病負擔和臨床未滿足的需求
• 妊娠和分娩統計數據分析
• 孕婦年齡層分析
• 分析產前篩檢實施情形
• 篩檢路徑與病人歷程分析
• 產前篩檢指引和臨床實踐概述

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新興技術
• 產品創新
• 臨床試驗分析
• 管道分析
• 技術藍圖
• 將人工智慧引入產前篩檢。
• 與數位健康融合

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：全球產前篩檢市場：展望分析

• 分析：按篩檢類型
• 分析：按技術平台
• 分析：依生物標記類型
• 分析：依檢體類型
• 分析：透過臨床應用
• 分析：透過測試方法
• 分析：按風險類別

第9章 全球產前篩檢市場：細分市場分析

• 按篩檢類型
  • 非侵入性產前篩檢（NIPS/NIPT）
  • 常規產前篩檢
    • 早期妊娠篩檢
    • 懷孕中期篩檢
    • 綜合和順序篩檢
• 透過技術平台
  • 次世代定序（NGS）
  • 基於微陣列的偵測
  • 採用PCR方法進行檢測
  • 生化免疫檢測
• 透過使用
  • 染色體數目異常
  • 微缺失症候群
  • 單基因疾病
  • 神經管異常及其他妊娠相關疾病
• 依檢體類型
  • 母體血
  • 母體血清
  • 其他類型的檢體
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 專科診所、不孕症治療中心
  • 學術研究機構

第10章 全球產前篩檢市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球產前篩檢市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 印度
• 韓國
• 澳洲
• 巴西
• 墨西哥
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 企業合併、商業夥伴關係和合作
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Natera, Inc.
• Revvity, Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings（Labcorp）
• BGI Genomics Co., Ltd.
• Myriad Genetics, Inc.
• Eurofins Scientific SE
• Agilent Technologies, Inc.

第14章 全球產前篩檢市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Prenatal Screening Market is expected to grow at a CAGR of 7.1% from a market value of USD 10.8 billion in 2026 to USD 20.0 billion in 2035.

The prenatal screening market is undergoing significant transformation driven by the paradigm shift toward non-invasive genomic assessment, rising maternal age, and the expanding clinical adoption of cell-free DNA-based screening. The market's evolution is characterized by the growing recognition that early identification of fetal chromosomal abnormalities, inherited disorders, and selected pregnancy-related complications enables informed clinical management, genetic counseling, and individualized pregnancy planning without exposing pregnancies to procedural risks. The convergence of next-generation sequencing, microarray analysis, and artificial intelligence is enabling faster, more accurate, and increasingly comprehensive prenatal genetic assessment. Healthcare systems are expanding screening utilization as maternal demographics shift toward older reproductive ages, elevating the probability of fetal chromosomal abnormalities and strengthening physician preference for earlier genomic assessment. Governments, professional societies, and regulatory organizations are continuously updating prenatal screening recommendations to reflect emerging clinical evidence, supporting broader implementation of validated screening technologies. The market is witnessing significant investment in expanded genomic panels, laboratory automation, and digital reporting platforms, positioning prenatal screening as a foundational component of precision maternal-fetal medicine and population-level maternal healthcare strategies.

Market Drivers

• The expanding clinical adoption of non-invasive prenatal screening represents the primary driver for the prenatal screening market. NIPS has become a preferred first-line genetic screening approach because it delivers high analytical sensitivity without exposing pregnancies to procedure-related risks. Clinical practice is increasingly transitioning toward cell-free DNA-based testing as healthcare providers seek earlier and more reliable fetal chromosomal assessment. This shift reduces reliance on invasive diagnostic procedures while improving patient acceptance of prenatal genetic evaluation. Diagnostic companies are expanding laboratory capacity and sequencing infrastructure to accommodate growing testing volumes. The market benefits from improved clinical confidence and broader integration of prenatal screening into routine obstetric care, resulting in sustained growth in prenatal screening utilization. Rising maternal age is further accelerating market growth through increased genetic screening demand. Advanced maternal age remains one of the strongest clinical risk factors for fetal chromosomal abnormalities. Many countries are experiencing delayed parenthood because educational attainment, workforce participation, and socioeconomic factors are influencing reproductive decisions. This demographic transition is increasing demand for comprehensive prenatal genetic assessment across both average-risk and high-risk pregnancies. Healthcare providers are incorporating molecular screening earlier during pregnancy to support informed clinical management. Continuous advances in next-generation sequencing technologies are improving analytical accuracy and laboratory throughput. NGS improves analytical accuracy by enabling comprehensive evaluation of fetal cell-free DNA with greater scalability than earlier molecular techniques. Sequencing platforms are becoming faster and more automated as manufacturers optimize workflow efficiency and bioinformatics integration. This technological progress reduces operational costs while supporting broader implementation across centralized laboratory networks. Expanding government and professional support for prenatal genetic screening is strengthening guideline-driven adoption. National healthcare organizations recognize prenatal genetic screening as an important component of maternal healthcare because early identification supports timely counseling and pregnancy management.

Market Restraints

• Limited reimbursement coverage across several developing healthcare systems restricts routine adoption of advanced prenatal genetic screening despite improving clinical evidence. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Ethical, legal, and social concerns surrounding prenatal genetic information continue influencing regulatory oversight and patient acceptance in several countries. The sensitive nature of prenatal genetic information creates challenges for implementation. Unequal access to genetic counseling and specialized molecular diagnostic laboratories limits screening availability across rural and resource-constrained healthcare settings. The shortage of specialized counselors and laboratories limits the scalability of advanced screening. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Screening Type Insights

• The technology landscape is characterized by the growing importance of integrated genomic platforms, automation, and AI-enabled analytics. NGS constitutes the leading technology platform because it enables comprehensive analysis of fetal cell-free DNA with high throughput and scalable laboratory workflows. Diagnostic providers are increasingly adopting advanced sequencing systems as lower sequencing costs and improved bioinformatics strengthen operational efficiency. This technological transition supports broader testing menus without substantially increasing laboratory complexity. Manufacturers continue improving sequencing chemistry, automation, and software integration to enhance analytical consistency across high-volume laboratories. The segment analysis reveals that NIPS represents the largest demand center because it combines high analytical performance with minimal clinical risk to both mother and fetus. Healthcare providers are increasingly recommending cell-free DNA screening as clinical evidence continues demonstrating superior sensitivity for common chromosomal aneuploidies compared with conventional serum-based approaches. Chromosomal aneuploidy screening accounts for the largest clinical application because trisomy 21, trisomy 18, and trisomy 13 remain the primary indications for prenatal genetic assessment. Clinical demand is increasing as healthcare providers prioritize earlier identification of pregnancies requiring confirmatory diagnostic testing and specialized clinical management. Diagnostic laboratories represent the leading end-user segment, with hospitals and specialty clinics expanding screening capabilities. The integration of AI is becoming increasingly important because AI enhances genomic data interpretation by improving variant classification, quality assessment, and laboratory workflow efficiency.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and sequencing companies alongside specialized prenatal genomics, laboratory, and testing service providers. Roche remains strategically distinct because it combines one of the world's largest in vitro diagnostics portfolios with extensive expertise in molecular diagnostics, PCR technologies, sequencing solutions, and automated laboratory systems, supporting clinical laboratories across the complete prenatal testing workflow. Illumina maintains strategic leadership because its sequencing platforms serve as foundational technology for a substantial proportion of global prenatal genomic testing, focusing on advancing sequencing chemistry, automation, and bioinformatics integration to improve laboratory efficiency and analytical performance. Natera differentiates itself through exclusive focus on cell-free DNA testing and proprietary molecular algorithms supporting reproductive health, having established strong physician recognition through extensive clinical validation of Panorama. Revvity occupies a differentiated position because it combines reproductive health diagnostics with laboratory automation, life sciences, and genomic technologies. Quest Diagnostics distinguishes itself through one of the largest diagnostic laboratory networks in North America, enabling broad physician access to prenatal genetic testing. Labcorp remains strategically important because it combines nationwide diagnostic laboratory operations with specialized genomic testing services across reproductive health. Companies are pursuing product portfolio expansion through innovation in expanded genomic panels, laboratory automation, and digital reporting platforms. Recent key developments include Myriad Genetics launching FirstGene as a multiple prenatal screen that runs four prenatal genetic screens simultaneously as early as eight weeks gestation. Gene Solutions presented evidence and clinical advances in prenatal genomics and women's health at ISPD 2026, highlighting NIPT-integrated carrier screening and AI-enabled pregnancy-risk assessment. EDAN introduced Nano OB Assist, an AI-enabled handheld ultrasound system designed to expand access to prenatal screening in low-resource settings. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The prenatal screening market is positioned for sustained growth driven by the convergence of NIPS adoption, demographic shifts, and technological innovation. The transition from conventional screening toward comprehensive non-invasive genomic assessment represents a fundamental shift in maternal-fetal medicine. While challenges related to reimbursement, ethical considerations, and access disparities persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with prenatal screening evolving into a foundational component of precision maternal healthcare, supporting earlier detection, informed decision-making, and improved outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Prenatal Screening Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Pregnancy & Prenatal Screening Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden & Unmet Clinical Needs
• 3.8 Pregnancy Population & Birth Statistics Analysis
• 3.9 Maternal Age Demographics Analysis
• 3.10 Prenatal Screening Adoption Analysis
• 3.11 Screening Pathway & Patient Journey Analysis
• 3.12 Prenatal Screening Guidelines & Clinical Practice Overview

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Technology Roadmap
• 6.6 Artificial Intelligence Integration in Prenatal Screening
• 6.7 Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Prenatal Screening Market Landscape Analysis

• 8.1 Analysis by Screening Type
• 8.2 Analysis by Technology Platform
• 8.3 Analysis by Biomarker Type
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Testing Methodology
• 8.7 Analysis by Risk Category

9. Global Prenatal Screening Market Segment Analysis (2021-2035)

• 9.1 By Screening Type
  • 9.1.1 Non-Invasive Prenatal Screening (NIPS/NIPT)
  • 9.1.2 Conventional Prenatal Screening
    • 9.1.2.1 First Trimester Screening
    • 9.1.2.2 Second Trimester Screening
    • 9.1.2.3 Integrated & Sequential Screening
• 9.2 By Technology Platform
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Microarray-Based Testing
  • 9.2.3 PCR-Based Testing
  • 9.2.4 Biochemical Immunoassays
• 9.3 By Application
  • 9.3.1 Chromosomal Aneuploidies
  • 9.3.2 Microdeletion Syndromes
  • 9.3.3 Single-Gene Disorders
  • 9.3.4 Neural Tube Defects & Other Pregnancy Conditions
• 9.4 By Sample Type
  • 9.4.1 Maternal Blood
  • 9.4.2 Maternal Serum
  • 9.4.3 Other Sample Types
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Specialty Clinics & Fertility Centers
  • 9.5.4 Academic & Research Institutes

10. Global Prenatal Screening Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Prenatal Screening Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Illumina, Inc.
• 13.3 Natera, Inc.
• 13.4 Revvity, Inc.
• 13.5 Quest Diagnostics Incorporated
• 13.6 Laboratory Corporation of America Holdings (Labcorp)
• 13.7 BGI Genomics Co., Ltd.
• 13.8 Myriad Genetics, Inc.
• 13.9 Eurofins Scientific SE
• 13.10 Agilent Technologies, Inc.

14. Global Prenatal Screening Market Commercial Forecast Analysis

• 14.1 Commercial Forecast by Non-Invasive Prenatal Screening (NIPS/NIPT)
• 14.2 Commercial Forecast by First Trimester Screening
• 14.3 Commercial Forecast by Second Trimester Screening
• 14.4 Commercial Forecast by Integrated & Sequential Screening
• 14.5 Commercial Forecast by Carrier Screening

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends